Investor Acorn Bioventures, L.p.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Acorn Bioventures, L.p. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-20 13G/A YMAB / Y-mAbs Therapeutics, Inc. 3,096,297 2,796,297
2025-08-15 13G/A YMAB / Y-mAbs Therapeutics, Inc. 2,761,825 3,096,297
2025-06-30 13G CADL / Candel Therapeutics, Inc. 2,580,517
2025-05-30 13D/A OKUR / OnKure Therapeutics, Inc. 2,839,674 2,839,674
2025-05-22 13D OKUR / OnKure Therapeutics, Inc. 1,439,674 2,839,674
2025-05-20 13G/A BCAB / BioAtla, Inc. 4,032,046 4,835,111
2025-02-14 13G/A MURA / Mural Oncology plc 1,286,079
2025-02-14 13G/A PBYI / Puma Biotechnology, Inc. 3,940,052
2024-11-14 13G/A PBYI / Puma Biotechnology, Inc. 2,934,496 3,279,440
2024-11-14 13G/A MURA / Mural Oncology plc 848,522 1,077,222
2024-10-09 13G OKUR / OnKure Therapeutics, Inc. 1,439,674
2024-08-13 13G MURA / Mural Oncology plc 848,522
2024-04-04 13D QTTB / Q32 Bio Inc. 803,425
2024-02-14 13G XFOR / X4 Pharmaceuticals, Inc. 17,755,869
2024-02-13 13G/A OPTN / OptiNose, Inc. 11,368,958 12,042,008
2024-02-07 13G/A CYCC / Cyclacel Pharmaceuticals, Inc. 2,815,146 0
2024-02-06 13G/A CRDF / Cardiff Oncology, Inc. 3,043,173 1,946,762
2024-02-06 13G/A YMAB / Y-mAbs Therapeutics, Inc. 2,326,528 2,761,825
2024-02-06 13G/A BCAB / BioAtla, Inc. 2,726,455 4,032,046
2024-02-06 13G/A PBYI / Puma Biotechnology, Inc. 2,739,935 2,934,496
2023-09-01 13G PBYI / Puma Biotechnology, Inc. 2,739,935
2023-04-27 13G BCAB / BioAtla, Inc. 2,726,455
2023-04-03 13G YMAB / Y-mAbs Therapeutics, Inc. 2,326,528
2023-01-26 13D/A CRDF / Cardiff Oncology, Inc. 5,990,839 3,043,173
2023-01-26 13G CRDF / Cardiff Oncology, Inc. 5,990,839 3,043,173
2023-01-26 13G/A CYCC / Cyclacel Pharmaceuticals, Inc. 2,344,491 2,815,146
2022-12-05 13G OPTN / OptiNose, Inc. 11,368,958
2021-02-12 13G CYCC / Cyclacel Pharmaceuticals, Inc. 2,344,491
2020-07-02 13D CRDF / Cardiff Oncology, Inc. 1,687,560 5,990,839
2020-06-04 13G CRDF / Cardiff Oncology, Inc. 1,687,560